By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharmaceuticals Receives Notice Of Allowance For Third US Patent For VAL-083 1/13/2015 7:32:48 AM
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015 8:27:57 AM
DelMar Pharmaceuticals Commences Offer To Exchange Common Stock For Outstanding Warrants 1/8/2015 9:35:19 AM
DelMar Pharmaceuticals To Present At Biotech Showcase™ 2015 1/7/2015 8:56:14 AM
DelMar Pharmaceuticals Joins OTCQX 12/3/2014 11:38:53 AM
DelMar Pharmaceuticals' Promising New Data Support The Potential Of VAL-083 To Meet Significant Unmet Medical Needs In The Treatment Of Glioblastoma Multiforme 11/17/2014 11:59:21 AM
DelMar Pharmaceuticals Presents Preclinical Data Supporting VAL-083 As A Potential New Treatment In Glioblastoma At The Society Of Neuro-Oncology Annual Meeting 11/14/2014 10:21:23 AM
DelMar Pharmaceuticals Announces September 30, 2014 Results And Provides Corporate Update 11/10/2014 9:32:53 AM
DelMar Pharmaceuticals Invited To Present New Data On VAL-083 In The Treatment Of Glioblastoma Multiforme At The Society For NeuroOncology Annual Meeting 11/6/2014 8:53:22 AM
DelMar Pharmaceuticals Release: VAL-083 Demonstrates Promise As A Potential Treatment For Non-Small Cell Lung Cancer 10/9/2014 9:12:45 AM